Eurofins Scientific SE
ERF: XPAR (FRA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€71.00 | Dmyhc | Kvbbtdjd |
Eurofins Maintains 2022 Guidance and Core Business Supports Growth; Maintaining FVE
Narrow-moat Eurofins reported solid third-quarter results with no change to its 2022 outlook, despite global macroeconomic headwinds and the war in Ukraine. Organic revenue growth and value-added acquisitions compensated for the decline in coronavirus sales year over year. We are maintaining our EUR 80 fair value estimate, and shares remain undervalued at EUR 62.